Standout Papers

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous s... 2016 2026 2019 2022 472
  1. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study (2016)
    Jacqueline A. French, John A. Lawson et al. The Lancet

Immediate Impact

1 by Nobel laureates 7 from Science/Nature 54 standout
Sub-graph 1 of 23

Citing Papers

mTOR and neuroinflammation in epilepsy: implications for disease progression and treatment
2024 Standout
Persistent physical symptoms: definition, genesis, and management
2024 Standout
1 intermediate paper

Works of Hiroko Ikeda being referenced

PNES around the world: Where we are now and how we can close the diagnosis and treatment gaps—an ILAE PNES Task Force report
2017
Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
2016 Standout

Author Peers

Author Last Decade Papers Cites
Hiroko Ikeda 455 571 242 646 56 2.3k
Akira Hashiramoto 189 1444 18 964 69 3.5k
Robert Langenbach 121 941 102 1248 37 3.4k
F. Nantel 85 1177 39 447 76 2.7k
Kenneth P. Chepenik 84 912 56 227 36 1.9k
Rama Pai 128 1459 65 750 65 3.3k
Yasuko Koshihara 82 1254 26 362 38 2.5k
Yoshikazu Miwa 76 1643 60 335 94 3.2k
Jeffrey L. Stock 47 2236 82 786 41 4.1k
Stephan Christgau 48 1203 36 700 63 4.2k
Kentaro Maemura 173 942 40 161 50 2.3k

All Works

Loading papers...

Rankless by CCL
2026